title: The benefits of tight glycemic control in type 2 diabetes mellitus.
abstract: Type 2 diabetes mellitus (DM) is associated with significantly increased risk of microvascular and macrovascular disease. Although most studies have focused on the microvascular complications of diabetes (eg, nephropathy, neuropathy, retinopathy), most patients with type 2 DM die from causes that are related to macrovascular disease (eg, myocardial infarction). Poor glycemic control increases the risk of future cardiovascular events, and prospective studies of patients with type 1 and type 2 DM have demonstrated that the incidence of vascular complications is reduced by lifestyle modifications or medications that reduce blood glucose concentrations.
authors.affiliation: Division of Endocrinology, Diabetes and Bone Disease, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10024, USA. derek.leroith@mssm.edu
authors.forename: Derek
authors.initials: D
authors.lastname: LeRoith
authors.forename: Elliot J
authors.initials: EJ
authors.lastname: Rayfield
mesh_terms: D001786:Blood Glucose / Q000032:analysis*; D015190:Blood Glucose Self-Monitoring; D063385:Cannabinoid Receptor Modulators / Q000037:antagonists & inhibitors; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000517:prevention & control*; D006442:Glycated Hemoglobin / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D054795:Incretins / Q000819:agonists; D007328:Insulin / Q000627:therapeutic use; D040242:Risk Reduction Behavior
chemical_list: D001786:Blood Glucose; D063385:Cannabinoid Receptor Modulators; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D054795:Incretins; D007328:Insulin